CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
CorMedix Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.38+0.12 (+1.65%)
Close on Oct 19, 2026
- Market cap
- $682.50M
- P/E (TTM)
- 3.6
- Dividend yield
- –
CorMedix Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product sales, net | $441.78M | $387.18M | $304.34M | $211.57M | $121.48M | $43.47M | 95.6% | +263.7% |
| Defen Cath | $343.62M | $317.24M | $258.81M | $198.79M | $121.48M | $43.47M | 74.3% | +182.9% |
| Melinta Portfolio | $98.16M | $69.94M | $45.53M | – | – | – | 21.2% | – |
| Contract revenue | $17.84M | $12.88M | $7.37M | – | – | – | 3.9% | – |
By region
From the segment and revenue-disaggregation notes of CorMedix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.